ethyl (E)-3-(pyrazolo[1,5-a]pyridin-2-yl)acrylate | 1206884-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: ethyl (E)-3-(pyrazolo[1,5-a]pyridin-2-yl)acrylate
• 英文别名: (E)-ethyl 3-(pyrazolo[1,5-a]pyridin-2-yl)acrylate；(E)-ethyl 2-(pyrazolo[1,5-a]pyridin-2-yl)acrylate；ethyl (E)-3-pyrazolo[1,5-a]pyridin-2-ylprop-2-enoate
• CAS: 1206884-56-1
• 化学式: C₁₂H₁₂N₂O₂
• 分子量: 216.239
• InChiKey: FPXQGJUPWNNEQK-VOTSOKGWSA-N

物化性质

• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-iminopyridinium ylide 在 palladium bromide 、 三(4-甲氧苯基)膦 、 silver benzoate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 21.08h， 生成 ethyl (E)-3-(pyrazolo[1,5-a]pyridin-2-yl)acrylate
  参考文献：
  名称：

  Synthesis of 2- and 2,3-Substituted Pyrazolo[1,5-a]pyridines: Scope and Mechanistic Considerations of a Domino Direct Alkynylation and Cyclization of N-Iminopyridinium Ylides Using Alkenyl Bromides, Alkenyl Iodides, and Alkynes

  摘要：

  Direct functionalization and tandem processes have both received considerable recent interest due to their cost and time efficiency. Herein we report the synthesis of difficult to obtain 2-substituted pyrazolo[1,5-a]pyridines through a tandem palladium-catalyzed/silver-mediated elimination/direct functionalization/cyclization reaction involving N-benzoyliminopyridinium ylides. As such, these biologically important molecules are prepared in an efficient, high-yielding manner, only requiring a two-step sequence from pyridine. Aryl-substituted alkenyl bromides and iodides are effective ylide coupling partners. Mechanistic studies led to the use of terminal alkynes, which extended the scope of the reaction to include alkyl substitution on the unsaturated reactive site. The optimization, scope, and mechanistic considerations of the process are discussed.

  DOI：

  10.1021/jo201303x

文献信息

• Synthesis of 2-Arylpyrazolo[1,5-a]pyridines by Suzuki–Miyaura Cross-Coupling Reaction
  作者：Shigeki Seto、Kentaro Umei、Yosuke Nishigaya、Megumi Kamiya、Yasushi Kohno

  DOI：10.1055/s-0034-1381025

  日期：——

  2-arylated pyrazolo[1,5-a]pyridine via pyrazolo[1,5-a]pyridine-2-yl triflate using the Suzuki–Miyaura­ ­­cross-coupling reaction is described. Fifteen 2-arylpyrazolo[1,5-a]pyridine derivatives were synthesized in 52–95% yields. Convenient access to a variety of 2-arylated pyrazolo[1,5-a]pyridine via pyrazolo[1,5-a]pyridine-2-yl triflate using the Suzuki–Miyaura­ ­­cross-coupling reaction is described. Fifteen

  摘要 方便地访问各种2-芳基化吡唑并[1,5-一个]吡啶吡唑并经由[1,5-一个]吡啶-2-基三氟甲磺酸酯使用被描述的Suzuki-Miyaura交叉偶联反应。合成了15种2-芳基吡唑并[1,5- a ]吡啶衍生物，产率为52-95％。 方便地访问各种2-芳基化吡唑并[1,5-一个]吡啶吡唑并经由[1,5-一个]吡啶-2-基三氟甲磺酸酯使用被描述的Suzuki-Miyaura交叉偶联反应。合成了15种2-芳基吡唑并[1,5- a ]吡啶衍生物，产率为52-95％。
• [EN] PYRIMIDINE PDE10 INHIBITORS<br/>[FR] INHIBITEURS PYRIMIDINES DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2013028590A1

  公开（公告）日：2013-02-28

  The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及嘧啶化合物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及利用这些化合物治疗神经系统和精神疾病，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的疾病。
• Synthesis of 2-Substituted Pyrazolo[1,5-<i>a</i>]pyridines through Cascade Direct Alkenylation/Cyclization Reactions
  作者：James J. Mousseau、Angélique Fortier、André B. Charette

  DOI：10.1021/ol902710f

  日期：2010.2.5

  from N-iminopyridinium ylides is described. These medicinally interesting compounds are formed through a cascade process involving a palladium-catalyzed direct alkenylation reaction followed by silver-mediated cyclization. The reaction can be performed with a wide range of electron-poor and electron-rich alkenyl iodides in good yields. This work represents perhaps the most direct route for the preparation

  描述了由N-亚氨基吡啶鎓的叶立德合成2-取代的吡唑并[1，5- a ]吡啶。这些医学上有趣的化合物是通过级联过程形成的，该过程涉及钯催化的直接烯基化反应，然后进行银介导的环化反应。该反应可与多种贫电子和富电子的烯基碘化物以高收率进行。这项工作可能代表了制备这些化合物的最直接途径。
• ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS
  申请人：Breslin Michael J.

  公开号：US20140336195A1

  公开（公告）日：2014-11-13

  The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及芳氧甲基环丙烷衍生物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这些化合物治疗神经系统和精神疾病，如精神分裂症、精神病或亨廷顿病等与纹状体低功能或基底节功能障碍有关的疾病。
• PYRIMIDINE PDE10 INHIBITORS
  申请人：Cox Christopher D.

  公开号：US20140228368A1

  公开（公告）日：2014-08-14

  The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及嘧啶化合物，其作为治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这些化合物治疗神经系统和精神疾病，例如精神分裂症、精神病或亨廷顿病以及与纹状体功能减退或基底节功能障碍相关的疾病。